BBP stock forecast, quote, news & analysis

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI), BioCryst Pharmaceuticals (NASDAQ:BCRX).

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 15B. The market cap for tickers in the group ranges from 62.21M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is BLUE at 62.21M.

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was -11%. For the same ETF, the average monthly price growth was -4%, and the average quarterly price growth was 9%. SWTX experienced the highest price growth at 7%, while AMLX experienced the biggest fall at -29%.

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 48%. For the same stocks of the ETF, the average monthly volume growth was 153% and the average quarterly volume growth was 127%